107 completed, 23 terminated, 21 active not recruiting, 15 recruiting. 188 Phase 1, 115 Phase 2.
Follow Lysosomal Storage Diseases: new trials by email Literature Review of Lysosomal Storage Diseases trials Research Report on Lysosomal Storage Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB rAAV9-CMV-hNAGLUop - Sanfilippo Syndrome (MPS III) | Phase 1 / Phase 2 | Not yet recruiting | NeuroGT | 9 | 2027-01-18 | 2026-09-14 |
| Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase - GM1 Gangliosidoses, GM1 Gangliosidosis, Type I | Phase 1 | Not yet recruiting | Tippi Mackenzie | 5 | 2027-01-01 | 2026-08-31 |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma GD2, PSMA and CD276 CAR-T cells - Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2026-12-31 | 2026-10-30 |
| A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD) S-606001 - Pompe Disease | Phase 1 | Not yet recruiting | Shionogi | 15 | 2026-11-30 | 2026-11-17 |
| Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU) scAAV9/AGA - Aspartylglucosaminuria, Aspartylglucosamidase (AGA) Deficiency | Phase 1 / Phase 2 | Enrolling by invitation | Rare Trait Hope | 9 | 2026-11-01 | 2026-10-27 |
| A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease VGN-R08b - Gaucher Disease Type 3 | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Vitalgen BioPharma Co., Ltd. | 12 | 2026-05-14 | 2026-05-22 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Disease DNL952 - Late-onset Pompe Disease | Phase 1 / Phase 2 | Recruiting | Denali Therapeutics Inc. | 32 | 2026-05-12 | 2026-11-18 |
| A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD) AB-1009 (GAA Gene) - Pompe Disease (Late-onset), Pompe Disease Late-Onset | Phase 1 / Phase 2 | Recruiting | AskBio Inc | 12 | 2026-04-15 | 2026-10-13 |
| Safety and Efficacy of AAV9. hMCOLN1co For Patients With Mucolipidosis Type IV AAV9.hMCOLN1co - Mucolipidosis Type IV | Phase 1 | Enrolling by invitation | The Children's Hospital of Zhejiang University School of Medicine | 1 | 2026-01-13 | 2026-02-10 |
| DFT383 in Pediatric Participants With Nephropathic Cystinosis DFT383 - Nephropathic Cystinosis | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 30 | 2025-06-02 | 2026-10-16 |
| The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease EXG110 Injection - Fabry Disease | Phase 1 / Phase 2 | Not yet recruiting | Guangzhou Jiayin Biotech Ltd | 16 | 2025-03-01 | 2025-02-11 |
| Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) GC1130A - Sanfilippo Syndrome Type A | Phase 1 | Active not recruiting | GC Biopharma Corp | 9 | 2024-11-21 | 2026-09-08 |
| An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB JR-446 - Mucopolysaccharidosis III-B | Phase 1 / Phase 2 | Active not recruiting | JCR Pharmaceuticals Co., Ltd. | 10 | 2024-11-05 | 2026-10-01 |
| A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants YH35995, Placebo - Healthy Participants | Phase 1 | Active not recruiting | Yuhan Corporation | 94 | 2024-07-29 | 2026-07-28 |
| A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I JWK008 Single intravenous infusion administration - Mucopolysaccharidosis Type I | Phase 1 | Recruiting | West China Hospital | 6 | 2024-07-22 | 2024-07-25 |
| A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease LY-M001 - Gaucher Disease Type 1 | Phase 1 / Phase 2 | Recruiting | Lingyi Biotech Co., Ltd. | 12 | 2024-07-05 | 2026-01-26 |
| Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease AMT-191 - Fabry Disease | Phase 1 / Phase 2 | Recruiting | UniQure Biopharma B.V. | 20 | 2024-06-05 | 2026-09-24 |
| Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2) FLT201 - Gaucher Disease, Type 1 | Phase 1 / Phase 2 | Active not recruiting | Spur Therapeutics | 75 | 2024-05-13 | 2025-11-04 |
| Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug GC301 - Pompe Disease (Late-onset) | Phase 1 / Phase 2 | Recruiting | GeneCradle Inc | 33 | 2024-04-19 | 2026-11-13 |
| Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) DNL126, Prophylactic immunomodulatory therapy - Mucopolysaccharidosis Type IIIA | Phase 1 / Phase 2 | Recruiting | Denali Therapeutics Inc. | 30 | 2023-12-07 | 2026-11-02 |
Showing 20 of 188. Sign in to see all of them.
Gaucher Disease (32) · Mucopolysaccharidosis I (28) · Fabry Disease (23) · Glycogen Storage Disease Type II (20) · Mucopolysaccharidosis II (20) · Mucopolysaccharidosis III (20) · Mucopolysaccharidoses (12) · Genetic Diseases, Inborn (11) · Leukodystrophy, Metachromatic (11) · Metabolic Diseases (11) · Metabolism, Inborn Errors (10) · Sudden Infant Death (10) · Mucopolysaccharidosis IV (8) · Niemann-Pick Disease, Type C (8)
Nutritional and Metabolic Diseases (188) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (187) · Metabolism, Inborn Errors (178) · Genetic Diseases, Inborn (177) · Metabolic Diseases (177) · Nervous System Diseases (133) · Brain Diseases (111) · Central Nervous System Diseases (111) · Brain Diseases, Metabolic (110) · Brain Diseases, Metabolic, Inborn (110) · Lysosomal Storage Diseases, Nervous System (110) · Carbohydrate Metabolism, Inborn Errors (94) · Lipid Metabolism, Inborn Errors (91) · Lipid Metabolism Disorders (89)
Iduronidase (6) · eliglustat (6) · migalastat (5) · 2-Hydroxypropyl-beta-cyclodextrin (4) · Sirolimus (4) · larazotide acetate (4) · valanafusp alpha (4) · Cysteamine (3) · GAA protein, human (3) · GALNS protein, human (3) · Methylprednisolone (3) · Rituximab (3) · fludarabine (3) · miglustat (3) · Acetylcysteine (2)
Shire (9) · Genzyme, a Sanofi Company (8) · Amicus Therapeutics (7) · ArmaGen, Inc (5) · JCR Pharmaceuticals Co., Ltd. (5) · BioMarin Pharmaceutical (4) · Duke University (4) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (4) · Protalix (4) · Sanofi (4) · Spur Therapeutics (4) · University of Florida (4) · Alexion Pharmaceuticals, Inc. (3) · Cyclo Therapeutics, Inc. (3) · Denali Therapeutics Inc. (3)
United States (115) · United Kingdom (39) · Germany (20) · Canada (17) · France (17) · Brazil (15) · Australia (13) · Netherlands (10) · Spain (10) · China (8) · Israel (7) · Italy (7) · Japan (7) · Denmark (6) · South Korea (5)
Joanne Kurtzberg, MD (4) · Forbes D Porter, M.D. (3) · Patrice Rioux, MD PhD (3) · Alan H Cohen, MD (2) · Caroline Hastings, MD (2) · Celeste Decker, MD (2) · Dugald Seely, ND (2) · Dwight D Koeberl, MD, PhD (2) · May Orfali, MD (2) · Patrice P Rioux, MD PhD (2)
PMID 37624739, PMID 22547151, PMID 25421091, PMID 29526614, PMID 29976218, PMID 33332761, PMID 35835061, PMID 36196048, PMID 36279795, PMID 36299240, PMID 11231629, PMID 11399225, PMID 15324318, PMID 19277123, PMID 19775921, PMID 19892975, PMID 19948615, PMID 20299511, PMID 21637107, PMID 22794786, PMID 23348766, PMID 23494656, PMID 23497636, PMID 23510062, PMID 23570273, PMID 23845948, PMID 23860343, PMID 23966770, PMID 24296492, PMID 24443373, PMID 25758611, PMID 26000324, PMID 26048034, PMID 27136905, PMID 27211612, PMID 27289174, PMID 27536442, PMID 28088251, PMID 28119821, PMID 28374935, PMID 28657663, PMID 28969890, PMID 30025991, PMID 30177353, PMID 30337566, PMID 30467742, PMID 30595526, PMID 30834538, PMID 31187454, PMID 31575939
2019 (3), 2009 (1), 2015 (1), 2017 (1), 2018 (1), 2023 (1), 2025 (1), K12CA120780 (1), P01HL059412 (1), U01HD090845 (1), U54NS065768 (1)